Development of a pharmacokinetic/pharmacodynamic/disease progression model in NC/Nga mice for development of novel anti-atopic dermatitis drugs
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baek, In-Hwan | - |
dc.contributor.author | Lee, Byung-Yo | - |
dc.contributor.author | Chae, Jung-Woo | - |
dc.contributor.author | Song, Gyu Yong | - |
dc.contributor.author | Kang, Wonku | - |
dc.contributor.author | Kwon, Kwang-Il | - |
dc.date.available | 2019-03-08T20:57:04Z | - |
dc.date.issued | 2014-11 | - |
dc.identifier.issn | 0049-8254 | - |
dc.identifier.issn | 1366-5928 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/11625 | - |
dc.description.abstract | 1. JHL45, a novel immune modulator against atopic dermatitis (AD), was synthesized from decursin isolated from Angelica gigas. The goal is to evaluate the lead compound using quantitative modeling approaches to novel anti-AD drug development. 2. We tested the anti-inflammatory effect of JHL45 by in vitro screening, characterized its in vitro pharmacokinetic (PK) properties. The dose-dependent efficacy of JHL45 was developed using a pharmacokinetics/pharmacodynamics/disease progression (PK/PD/DIS) model in NC/Nga mice. 3. JHL45 has drug-like properties and pharmacological effects when administered orally to treat atopic dermatitis. The developed PK/PD/DIS model described well the rapid metabolism of JHL45, double-peak phenomenon in the PK of decursinol and inhibition of IgE generation by compounds in NC/Nga mice. Also, a quantitative model was developed and used to elucidate the complex interactions between serum IgE concentration and atopic dermatitis symptoms. 4. Our findings indicate that JHL45 has good physicochemical properties and powerful pharmacological effects when administered orally for treatment of AD in rodents. | - |
dc.format.extent | 13 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | INFORMA HEALTHCARE | - |
dc.title | Development of a pharmacokinetic/pharmacodynamic/disease progression model in NC/Nga mice for development of novel anti-atopic dermatitis drugs | - |
dc.type | Article | - |
dc.identifier.doi | 10.3109/00498254.2014.924058 | - |
dc.identifier.bibliographicCitation | XENOBIOTICA, v.44, no.11, pp 975 - 987 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000343080900003 | - |
dc.identifier.scopusid | 2-s2.0-84911487926 | - |
dc.citation.endPage | 987 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 975 | - |
dc.citation.title | XENOBIOTICA | - |
dc.citation.volume | 44 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Atopic dermatitis | - |
dc.subject.keywordAuthor | disease progression model | - |
dc.subject.keywordAuthor | drug development | - |
dc.subject.keywordAuthor | pharmacodynamics | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
dc.subject.keywordPlus | DOUBLE-PEAK PHENOMENON | - |
dc.subject.keywordPlus | ANGELICA-GIGAS | - |
dc.subject.keywordPlus | MOUSE MODEL | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | DISCOVERY | - |
dc.subject.keywordPlus | PATHOPHYSIOLOGY | - |
dc.subject.keywordPlus | PERMEABILITY | - |
dc.subject.keywordPlus | SOLUBILITY | - |
dc.subject.keywordPlus | ABSORPTION | - |
dc.subject.keywordPlus | RESPONSES | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Toxicology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Toxicology | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.